Model‐based population pharmacokinetic analysis of tislelizumab in patients with advanced tumors

• Ngā kaituhi matua: Nageshwar Budha (Author), Chi‐Yuan Wu (Author), Zhiyu Tang (Author), Tian Yu (Author), Lucy Liu (Author), Fengyan Xu (Author), Yuying Gao (Author), Ruiying Li (Author), Qiuyang Zhang (Author), Ya Wan (Author), Srikumar Sahasranaman (Author)
• Hōputu: Pukapuka
• I whakaputaina: Wiley, 2023-01-01T00:00:00Z.
• Ngā marau: article
• Urunga tuihono: Connect to this object online.

Abstract Tislelizumab, a humanized immunoglobulin G4 monoclonal antibody, is a programmed cell death protein 1 (PD‐1) inhibitor designed to minimize Fc gamma receptor binding on macrophages to limit antibody‐dependent phagocytosis, a potential mechanism of resistance to anti-PD‐1 therapy. The pharma...